Protection by design

MEVOX combines in-house expertise with world class partnerships in antigen design and vaccine development. We leverage this cutting-edge vaccine innovation and translational expertise to bring established vaccines into the 21st century and address significant unmet needs.


MEVOX brings vaccinology into the 21st century. We translate cutting-edge molecular characterization, design and engineering into conformationally precise and optimized protein vaccines. These induce 10-100 times higher neutralising antibody levels than existing vaccines, also showing sterilizing and durable immunity. We embed this scientific excellence in partnerships with world leaders on our target diseases with antigen design and translation. Our goal is global health impact through protection by design.


Ken Kelley, Stephanie Monaghan O’Brien and Guillaume Stewart-Jones are part of the board.

Stephanie O’brien

unnamed (52)

Guillaume Stewart-Jones

Sans titre

Ken Kelley

ken kelly

and our investors

Our Values

Vaccine Architects Engineering
Protection by design

Contact Us